Publications by authors named "Maria Vilenchik"

Claim this Profile
A
A novel dual DYRK1A/B inhibitor for the treatment of type 1 diabetes.
Šarūnas Tumas, Jonas Mingaila, Vytautas Baranauskas, Emilija Baltrukonytė, Laurynas Orla, Maria Vilenchik

Front Pharmacol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel Efficient Multistage Lead Optimization Pipeline Experimentally Validated for DYRK1B Selective Inhibitors.
Vadim Alexandrov, Maria Vilenchik, Omar Kantidze, Nika Tsutskiridze, Daviti Kharchilava

J Med Chem· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Cell Double-Barcoding System for Quantitative Evaluation of Primary Tumors and Metastasis in Animals That Uncovers Clonal-Specific Anti-Cancer Drug Effects.
Arkadi Hesin, Santosh Kumar, Valid Gahramanov, Maria Becker, Maria Vilenchik

Cancers (Basel)· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
DYRK1A regulates B cell acute lymphoblastic leukemia through phosphorylation of FOXO1 and STAT3.
Rahul S Bhansali, Malini Rammohan, Paul Lee, Anouchka P Laurent, Qiang Wen, Maria Vilenchik

J Clin Invest· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
How to design potent and selective DYRK1B inhibitors? Molecular modeling study.
Agnieszka Szamborska-Gbur, Ewelina Rutkowska, Agnieszka Dreas, Michael Frid, Maria Vilenchik

J Mol Model· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inactivation of mirk/dyrk1b kinase targets quiescent pancreatic cancer cells.
Daina Z Ewton, Jing Hu, Maria Vilenchik, Xiaobing Deng, Kin-Chun Luk

Mol Cancer Ther· November 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical profile of a potent gamma-secretase inhibitor targeting notch signaling with in vivo efficacy and pharmacodynamic properties.
Leopoldo Luistro, Wei He, Melissa Smith, Kathryn Packman, Maria Vilenchik

Cancer Res· October 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Selective compounds define Hsp90 as a major inhibitor of apoptosis in small-cell lung cancer.
Anna Rodina, Maria Vilenchik, Kamalika Moulick, Julia Aguirre, Joungnam Kim

Nat Chem Biol· August 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hsp90: the vulnerable chaperone.
Gabriela Chiosis, Maria Vilenchik, Joungnam Kim, David Solit

Drug Discov Today· October 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting wide-range oncogenic transformation via PU24FCl, a specific inhibitor of tumor Hsp90.
Maria Vilenchik, David Solit, Andrea Basso, Henri Huezo, Brian Lucas

Chem Biol· June 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Microtiter cell-based assay for detection of agents that alter cellular levels of Her2 and EGFR.
Henri Huezo, Maria Vilenchik, Neal Rosen, Gabriela Chiosis

Chem Biol· July 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antisense RNA down-regulation of bcl-xL Expression in prostate cancer cells leads to diminished rates of cellular proliferation and resistance to cytotoxic chemotherapeutic agents.
Maria Vilenchik, Anthony J Raffo, Luba Benimetskaya, David Shames, C A Stein

Cancer Res· April 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis